Immunotherapies for Opioids to Prevent Relapse and Overdose
The Research Need
Relapse and death from drug overdose are major challenges for the treatment of opioid use disorder (OUD). Communities urgently need additional strategies for treating opioid addiction and preventing overdose, such as vaccines that reduce the euphoric effects of opioids and offer protection from overdose. Currently, there are no licensed vaccines for the treatment of substance use disorders.
About the Program
Through the Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM, NIH has established a coordinated, multidisciplinary consortium to develop anti-opioid vaccines and monoclonal antibodies and test their safety and efficacy in clinical trials. The goal is to have immunotherapies approved by the U.S. Food and Drug Administration (FDA) for opioid use disorder and overdose.
To date, through the NIH HEAL Initiative, NIH has awarded 10 grants and contracts for new research projects. These awards total almost $55 million. The consortium supported by this funding will take advantage of the National Institute of Allergy and Infectious Diseases' (NIAID) vaccine development programs and resources as well as the National Institute on Drug Abuse’s (NIDA) expertise in opioid biology and the management of opioid use disorder.
- Boston Children’s Hospital – Massachusetts
- Butler University – Rhode Island
- Duke University – North Carolina
- Hennepin Healthcare Research Institute – Minnesota
- Henry M. Jackson Foundation for the Advancement of Military Medicine – Maryland
- Scripps Research Institute – Florida
- Tulane University – Louisiana
- University of Chicago – Illinois
- University of Montana – Montana
- University of New Mexico Health Science Center – New Mexico
- University of Texas Medical Branch – Texas
Participating NIH Institutes, Centers, and Offices
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute on Drug Abuse (NIDA)